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Olsen CM, Huang Y, Goodwin S, Ciobanu DC, Lu L, Sutter TR,
Winder DG. Microarray analysis reveals distinctive signaling between
the bed nucleus of the stria terminalis, nucleus accumbens, and dorsal
striatum. Physiol Genomics 32: 283–298, 2008. First published October
2, 2006; doi:10.1152/physiolgenomics.00224.2006.—To identify distinct
transcriptional patterns between the major subcortical dopamine targets
commonly studied in addiction we studied differences in gene expression
between the bed nucleus of the stria terminalis (BNST), nucleus accum-
bens (NAc), and dorsal striatum (dStr) using microarray analysis. We first
tested for differences in expression of genes encoding transcripts for
common neurotransmitter systems as well as calcium binding proteins
routinely used in neuroanatomical delineation of brain regions. This a
priori method revealed differential expression of corticotropin releasing
hormone (Crh), the GABA transporter (Slc6a1), and prodynorphin
(Pdyn) mRNAs as well as several others. Using a gene ontology tool,
functional scoring analysis, and Ingenuity Pathway Analysis, we further
identified several physiological pathways that were distinct among these
brain regions. These two different analyses both identified calcium
signaling, G-coupled protein receptor signaling, and adenylate cyclase-
related signaling as significantly different among the BNST, NAc, and
dStr. These types of signaling pathways play important roles in, amongst
other things, synaptic plasticity. Investigation of differential gene expres-
sion revealed several instances that may provide insight into reported
differences in synaptic plasticity between these brain regions. The results
support other studies suggesting that crucial pathways involved in neu-
rotransmission are distinct among the BNST, NAc, and dStr and provide
insight into the potential use of pharmacological agents that may target
region-specific signaling pathways. Furthermore, these studies provide a
framework for future mouse-mouse comparisons of transcriptional pro-
files after behavioral/pharmacological manipulation.
mouse; brain; Ingenuity Pathways knowledge database; functional
class scoring; gene ontology
DOPAMINERGIC TRANSMISSION plays a key role in many aspects of
motivated behavior and plays important roles in pathophysio-
logical states such as addiction and Parkinson’s disease. Do-
paminergic innervation of the central nervous system emanates
predominantly from discrete midbrain and brainstem nuclei.
The two major centers are the substantia nigra (SN) and the
ventral tegmental area (VTA) (17); however, other nuclei, such
as the periaqueductal gray (PAG), are also thought to be
important contributors (4). These centers provide only partially
overlapping innervation of the forebrain. The primary subcor-
tical structures innervated by these regions are the dorsal
striatum (dStr), nucleus accumbens (NAc), and bed nucleus of
the stria terminalis (BNST), for the SN, VTA, and VTA/PAG,
respectively (13, 44). As with dopaminergic transmission in
general, these brain regions have similarly been implicated in
pathophysiological states ranging from Parkinson’s disease to
drug addiction (24, 25, 64, 118).
Among the dStr, NAc, and BNST, characteristics such as
cell morphology and the presence of particular neuropeptides
are similar (58, 59), although specific afferents and efferents
are varied (20, 30, 48). A common feature of these three
regions is that they integrate cortical and subcortical inputs to
shape appropriate behavioral responses to stimuli (15, 63, 82).
The dStr is primarily involved in motor function and initiation
of movement (36, 50), the NAc is associated with the transla-
tion of motivational states into behavior (74), and the BNST
has been associated with stress, anxiety and the expression of
“fight or flight” responses (29).
The dStr, NAc, and BNST likely play distinct roles in
addiction. The dStr is known to be involved in habit learning
(38, 79), and drug-induced plasticity in the dStr has been
proposed to underlie the compulsive nature of addiction (25,
34). Emerging evidence also suggests that the dStr may play an
important role in relapse (27, 31, 110) and craving (101) after
abstinence. The NAc has been associated with the acute rein-
forcing effects of both natural and drug reinforcers (10, 117,
119). It is also known to undergo extensive neuroadaptations
(76, 114) and is crucial for the expression of reinstatement, an
animal model of drug relapse (61). The BNST has been
proposed to mediate stress and reward interactions, especially
in regards to addiction (18, 104). Interruption of signaling
within the BNST reduces the behavioral signs of morphine (5)
and ethanol (89) withdrawal and prevents stress-induced drug-
seeking in animals that previously self-administered cocaine
(24). To further elucidate similarities and differences in these
addiction-related brain regions, we performed microarray anal-
ysis on each tissue to compare transcriptional profiles between
them.
MATERIALS AND METHODS
Animals
Male C57BL/6J mice obtained from Jackson Laboratories (Bar
Harbor, ME) were housed in the Vanderbilt Animal Care Facilities in
groups of four or five and were 12 wk old at the time of death. Male
Penk1-EGFP BAC-transgenic hemizygous mice were bred from a
founder line purchased from the Mutant Mouse Regional Resource
Article published online before print. See web site for date of publication
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Address for reprint requests and other correspondence: D. G. Winder, Dept.
of Molecular Physiology & Biophysics, 23rd and Pierce Ave. S., Rm. 724B,
RRB, Vanderbilt Univ. School of Medicine, Nashville, TN 37232-0615
(e-mail: danny.winder@vanderbilt.edu).
Physiol Genomics 32: 283–298, 2008.
First published October 2, 2006; doi:10.1152/physiolgenomics.00224.2006.
1094-8341/08 $8.00 Copyright © 2008 the American Physiological Society 283
Centers (http://www.mmrrc.org/). Mice were maintained in tempera-
ture- and humidity-controlled rooms and kept on a 12-h light/dark
cycle, with the lights on from 0600 to 1800 h. Food and water were
available ad libitum. Experiments were conducted in accordance with
the National Institutes of Health guidelines for the care and use of
animals and were approved by the Vanderbilt University Animal Care
and Use Committee.
Tissue Dissection
Mice were briefly anesthetized with isoflurane and then rapidly
decapitated. Brains were submerged in oxygenated (95% O2-5% CO2)
ice-cold sucrose-artificial cerebrospinal fluid solution (in mM: 194
sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0
glucose, and 26.0 NaHCO3), and coronal brain slices (300 m) were
made with a vibratome (Leica). Slices were transferred onto a glass
Petri dish with a transfer pipette, and excess fluid was drained from
the area surrounding the tissue. The Petri dish was placed on top of a
chilled aluminum block, and tissue was brought to a semifrozen state
before punches were taken. Punches (0.50 mm; Fine Science Tools,
Foster City, CA) were taken from slices containing NAc (bregma
1.18), dStr (bregma 0.86) and BNST (bregma 0.14, see Fig. 1).
Bilateral punches for each region were pooled into frozen sample
tubes and stored at 80°C as identified from the atlas of Paxinos and
Franklin (81). Tissue for quantitative reverse transcriptase polymerase
chain reaction (qPCR) consisted of bilateral punches from three mice
pooled together per sample. As a result, tissue from nine mice was
used to obtain an n of 3 for qPCR.
Visualization of Penk1-driven EGFP expression
For visualizing enhanced green fluorescent protein (EGFP) expres-
sion, we obtained brain slices from a Penk1-EGFP mouse as described
and transferred them to glass-bottom culture dishes (MatTek, Ash-
land, MA). Slices were observed under a stereomicroscope equipped
with a GFP filter set (SZX12; Olympus, Center Valley, PA) under
identical illumination and exposure. Images were acquired with a
Fig. 1. Diagram of punches taken from nucleus accumbens (NAc), dorsal
striatum (dStr), and bed nucleus of the stria terminalis (BNST). We took 0.5
mm punches as illustrated from 300 m sections at the approximate coordi-
nates shown. Figure adapted from Ref. 81.
Fig. 2. Pair-wise variance of all present genes. Difference vs. average (MA)
plots of each pair-wise comparison. The percentage of genes differing by 2
log2 units (¥) is displayed for each comparison.
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QICAM monochrome camera and QCapture software (QImaging,
Burnaby, BC, Canada). Images were analyzed for fluorescence inten-
sity using ImageJ (88). Briefly, a circular region of interest approxi-
mating the size of the punches was placed over each brain region, and
the mean intensity of the region was measured. This was done for each
hemisphere, and the mean of the two hemispheres was reported (see
Fig. 5C). Following analysis, images were pseudocolored and overlaid
with wireframes adapted from a mouse brain atlas (see Fig. 5, A
and B) (81).
RNA Amplification, Target Synthesis, and Microarray Analysis
Amplification of RNA isolated from tissue was required to provide
sufficient material for target synthesis (28, 109). Total RNA was
isolated from the frozen tissue using Stat-60 (Tel-Test, Friendswood,
TX). The RNA was resuspended in RNase-free water, and the con-
centration was determined using a NanoDrop Spectrophotometer
(NanoDrop Technologies, Rockland, DE). To ensure that high-quality
RNA was obtained, 1 l of each sample was analyzed on a Agilent
Bioanalyzer 2100 using the RNA 6000 Pico Series II (Agilent tech-
nologies, Palo Alto, CA). Starting with 10 ng of total RNA, cRNA
targets were generated by the two-cycle target labeling method (1,
22). Briefly, first-strand cDNA synthesis using a T7(dT)24 oligonu-
cleotide was followed by second-strand cDNA synthesis (Invitrogen
Life Technologies, Carlsbad, CA). The double-stranded cDNA was
ethanol precipitated, washed, and resuspended in water. In vitro
transcription of the double-stranded cDNA was performed using
MEGAscript T7 High Yield Transcription kit (Ambion, Austin, TX).
Incubation was performed for 6 h at 37°C, and the sample was purified
using a RNA-easy clean-up kit (Qiagen, Valencia, CA). For the
second round of cDNA synthesis, cRNA and 200 ng random primers
(Invitrogen) were denatured for 10 min at 70°C and cooled on ice for
2 min, followed by first-strand synthesis (Invitrogen). The mixture
was incubated at 42°C for 1 h, followed by the addition of 2 units
RNase H, and then incubated at 37°C for 20 min, followed by 95°C
for 5 min. T7(dT)24 oligonucleotide (5 M) was added, and the
mixture was incubated for 6 min at 70°C and then cooled on ice.
Second-strand cDNA synthesis was performed as described above.
Biotin-labeled cRNA was produced using the ENZO BioArray High
Yield RNA Transcript Labeling Kit (Enzo Biochemical, New York,
NY) according to the manufacturer’s instructions. Labeled cRNA was
purified, and 20 g of cRNA was fragmented to a range of 35–200
bases in length. Samples were hybridized at 45°C for 16 h to
Affymetrix mouse430_2 chips (containing 54k probe sets) according
to standard GeneChip Expression assay protocol (1). After hybridiza-
tion, the chips were washed and scanned using a GeneChip Scanner.
The P (Present)- or A (Absent)-calls of the probe sets in the gene
Fig. 3. Expression profile of a priori genes in dStr, NAc,
and BNST. The 30 most differential genes from the a priori
list were displayed using dChip.
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expression chips were determined by the Affymetrix GCOS v1.4.
Chip quality, including RNA degradation, cDNA synthesis, hybrid-
ization, chip washing and scanning, was evaluated with GCOS v1.4,
dChip and Bioconductor “affy” package. All RNA samples and chips
adopted in current study passed the quality criteria (Supplemental
Table S1 and Supplemental Fig. S1).1 The intensities of probe sets
were calculated by dChip software with Perfect-match/Mismatch
difference model after invariant-set normalization (65). The microar-
ray data have been submitted to the National Center for Biotechnol-
ogy Information’s Gene Expression Omnibus repository (series ac-
cession no. GSE5763).
qPCR Analysis
Total RNA was extracted from the frozen tissue using Stat-60
(Tel-Test). The RNA was suspended in RNase-free water, and its
quality and quantity were determined using an Agilent-Bioanalyzer
2100. The total RNA was treated with DNase I (DNA-free kit;
Ambion, Austin, TX) to remove any traces of DNA that could
contaminate the samples and interfere with quantification. Following
DNase treatment the RNA concentration was quantified using a
NanoDrop spectrophotometer. cDNA synthesis was performed on
equal amounts of total RNA per sample using random hexamers
following the protocol provided by manufacturer (First strand cDNA
Synthesis Kit; GE Healthcare Bio-Sciences, Piscataway, NJ). PCR
amplification of a fragment of Ppp1r13b (Mm.313076) spanning a
small intron did not show any evidence of genomic DNA contami-
nation.
Genes that contributed to Ingenuity Pathway Analysis (IPA) results
were considered for qPCR validation. We selected genes differentially
expressed between 1) BNST and NAc and 2) BNST and dStr and used
qPCR assays approximating microarray probe location. The quantita-
tive RT-PCR assays were selected using Universal Probe Library
(www.universalprobelibrary.com, Roche Diagnostics, IN) (Supple-
mental Table S4). Most of the assays used span an intron while the
remaining few targeted the 3 untranslated region. The expression of
these genes was measured using qPCR assays with cyclophilin D as a
reference gene for comparative threshold quantification. This refer-
ence gene is not differentially expressed among three regions. Quan-
titative reverse transcriptase-polymerase chain reaction (RT-PCR)
was performed using a LightCycler 480 System (Roche Diagnostics)
and the standard protocol for the LC480 Probes Master (Roche
Diagnostics). The efficiency of PCR amplification was performed for
each of the assay using mouse (C57BL/6J) forebrain RNA. The
expression of each gene was normalized by simultaneously assessing
the reference gene in each experimental sample. Each experimental
sample was assayed in duplicate. Standard curves for five 10-fold
dilution steps between 2,500 and 0.25 ng of reverse-transcribed RNA
samples were run for all primer pairs to determine the PCR efficiency
under the experimental conditions for the reference and all selected
genes. All PCR reactions including standard curves were performed in
technical duplicates.
Data Analysis
For a priori analysis, we tested a list of genes encoding tran-
scripts involved in common neurotransmitter systems as well as
calcium binding proteins routinely used in neuroanatomical delin-
eation of brain regions. We compiled this list prior to any analysis
to include genes encoding prohormones, synthesis and degradation
enzymes, transporters, and receptor subunits for common neuro-
transmitters (Supplemental Table S2). Only probe sets with P calls1 The online version of this article contains supplemental material.
Fig. 4. In situ hybridization showing enrichment of corticotropin releasing hormone (Crh) in BNST. Coronal sections of mouse brain showing low expression
of Crh in dStr and NAc (left) and high expression of Crh in the BNST relative to adjacent striatum (right). Images taken from the Allen Brain Atlas
(www.brain-map.org). Image IDs: Crh_326_2040 (left) and Crh_294_2040 (right).
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in all three replicates of at least one brain region were used.
Expression values for a priori transcripts from all three brain regions
were analyzed by ANOVA followed by uncorrected Fisher’s least
significant difference comparisons, and the most significant genes
were displayed by hierarchical clustering in dChip using the default
clustering algorithm (65).
Transcriptional network and pathway analysis was performed on
pair-wise comparisons between brain regions by two methods previ-
ously shown to give complementary results using different algorithms
(51). First, functional class scoring (FCS) analysis was performed
with the software downloaded from www.geneontology.org/GO.
tools.microarray.shtml#ermine and implemented in a JAVA environ-
ment. FCS was used on a list of all transcripts that were expressed
(determined by P calls) in 3/3 replicates for at least one region in the
pair-wise comparison. The intensities of the expressed genes were
analyzed by unpaired t-test followed by Benjamini-Hochberg proce-
dure to correct P value (called q-value) for multiple tests using
GeneSpring v7.0 (Agilent Technologies). For repeated occurrence of
a gene (a gene was represented by 2 or more probe sets in the chips),
only the best (minimum) q-value was used in FCS analysis (80).
Second, IPA (http://www.ingenuity.com) was performed on differen-
tially expressed genes (“focus genes”) that met these criteria:
1) expressed in 3/3 replicates for at least one region in the comparison,
2) a fold difference 1.5, 3) signal intensity difference 60 and
4) q-value 0.065. IPA uses a powerful database, the Ingenuity
pathways knowledge base (IPKB), to reveal biological pathways that
are significantly different among sample groups. The IPKB is a
database curated by scientists that includes hundreds of thousands of
modeled relationships between genes, proteins, anatomy, biological
processes, and disease. The significance of a pathway is controlled by
P value, which is calculated using the right-tailed (referring here to the
overrepresented pathway) Fisher Exact Test for 2  2 contingency
tables. This is done by comparing the number of “focus genes” that
participate in a given canonical pathway, relative to the total number
of occurrences of those genes in all networks or pathways stored in the
IPKB. The significance threshold of pathways was set to 1.3 (derived
by log10 [P value], whereas P  0.05).
Validation of Ingenuity Results Using the Allen Brain Atlas
The top five canonical pathways revealed by IPA were subject to
validation using an independent measure of gene expression. Individ-
ual genes contributing to differences in IPA (see Tables 2–5 and S3
for gene lists) were queried using the Allen Brain Atlas (www.brain-
map.org), and images of coronal sections including BNST, NAc, and
Str from in situ hybridization experiments were acquired (see Figs. 4
and 7 for representative images). For consistency, expression studies
not available in coronal format were not used. From the acquired
images, square regions of interest approximating the size and place-
ment of our tissue punches (see Fig. 1) were analyzed for the number
of labeled cells using ImageJ (88) by an experimenter blind to
microarray results. Cell counts in pair-wise comparisons were repre-
sented as relative abundance values (RAVs, number of labeled cells in
region 1/region 2) and compared with RAVs derived from microarray
analysis. Regression analysis was performed on RAVs from the cell
counts and microarray data (see Fig. 8A) and Pearson correlation
coefficients were reported (Fig. 8B).
Validation of Ingenuity Results using qPCR
The mean crossing thresholds (CT) obtained for the technical
duplicates of the different amplicons were statistically processed to
calculate mean normalized expression (MNE) values that reflect the
relative expression of the target gene compared with the reference
gene by taking the efficiencies of the PCR reaction into account (100).
MNE values were log10 transformed and compared by Bonferroni
corrected t-tests within each pair-wise comparison (i.e., BNST vs.
Str). Mean fold difference values were calculated using the expression
Fig. 5. Expression of enhanced green fluorescent protein (EGFP) under the
control of the Penk1 promoter. A and B: coronal sections of mouse brain
showing expression of EGFP reporter under the control of the Penk1 promoter.
C: quantification of EGFP luminance for each region. Wireframe diagrams
adapted from Ref. 81. Aca, anterior commissure; AcbC and AcbSH, nucleus
accumbens core and shell; BST, bed nucleus of the stria terminalis; LD, lateral
dorsal; LJ, lateral juxtacapsular; LP, lateral posterior; MA, medial anterior.
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Fig. 6. Ingenuity pathway analysis showing all canonical pathways significantly different in pair-wise comparisons. Pathways shown include all pathways
significantly different in at least one pair-wise comparison.
Table 1. Functional class scoring analysis
A. BNST vs. dStr
ID Name
Probes
P ValueTotal Present
GO:0006813 potassium ion transport 135 78 0.0029
GO:0007200 G protein signaling, coupled to IP3 second messenger (phospholipase C activating) 66 37 0.0041
GO:0007190 adenylate cyclase activation 35 25 0.0221
GO:0009190 cyclic nucleotide biosynthesis 15 13 0.0227
GO:0007610 behavior 153 97 0.0396
GO:0007411 axon guidance 104 57 0.0437
GO:0007189 G protein signaling, adenylate cyclase activating pathway 45 30 0.0443
GO:0009966 regulation of signal transduction 119 69 0.0465
GO:0009593 detection of chemical stimulus 31 13 0.0474
GO:0045055 regulated secretory pathway 102 52 0.0488
GO:0051057 positive regulation of small GTPase mediated signal transduction 7 5 0.0500
B. BNST vs. Nac
ID Name
Probes
P ValueTotal Present
GO:0006887 exocytosis 132 70 0.0151
GO:0050804 regulation of synaptic transmission 21 10 0.0356
GO:0001525 angiogenesis 58 41 0.0405
GO:0050769 positive regulation of neurogenesis 22 11 0.0426
GO:0007200 G protein signaling, coupled to IP3 second messenger (phospholipase C activating) 64 35 0.0440
GO:0006883 sodium ion homeostasis 12 6 0.0451
GO:0016337 cell-cell adhesion 158 100 0.0462
GO:0017157 regulation of exocytosis 29 15 0.0464
C. NAc vs. dStr
ID Name
Probes
P ValueTotal Present
GO:0009593 detection of chemical stimulus 30 13 0.0011
GO:0005513 detection of calcium ion 30 13 0.0023
GO:0030198 extracellular matrix organization and biogenesis 49 27 0.0254
GO:0030073 insulin secretion 17 9 0.0345
GO:0045898 regulation of transcriptional preinitiation complex formation 19 5 0.0406
GO:0030199 collagen fibril organization 12 9 0.0486
The most significant functional classes from pair-wise analysis between BNST and dStr (A), BNST and NAc (B), and NAc and dStr (C). Total probes refers
to total probe sets in the chip. Present probes refers to probe sets in 3/3 chips in one or both of the compared brain regions. BNST, bed nucleus of the stria
terminalis; dStr, dorsal striatum; NAc, nucleus accumbens.
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in BNST (BNST vs. Str and BNST vs. NAc comparisons) or NAc
(NAc vs. Str comparisons) as a reference.
RESULTS
Quality Control
The 260/280 ratio of total RNA in water was1.7, while the
cRNA concentration was 2.4 g/l for all samples. The chip
quality was checked by GCOS v1.4, with RawQ 2, Scaling
factor 8.5, Background 60, percentage of P calls 42% for
every sample (actual values in Supplemental Table S1). How-
ever, the range of actin 3/5 and GAPDH 3/5 was 3.2–9.6.
This was caused by the 2nd round cDNA amplification proto-
col, whereas the oligo(dT) primers were used twice in the
procedure, and thus significantly increased the amplification at
3 (22, 109). The chip quality was further validated by dChip.
“Array outlier” was 0.37% and “single outlier” 0.05%
(65). The affy package of Bioconductor was used to generate
an RNA degradation plot for each array. On each chip, probe
intensities were averaged by location in probe set, with the
average taken over all probe sets (Supplemental Fig. S1). The
large slopes confirmed the higher amplification efficiency in 3.
Importantly, the slopes are similar across all chips, indicating
there was no RNA degradation and the efficiency of cDNA
amplification synthesis was consistent among samples. There
was no chip outlier inferred by the two-round cDNA amplifi-
cation protocol in the current study.
Pair-wise Variance of All Expressed Genes
Expressed genes (P calls in 3/3 replicates) were represented
as log2 signal intensity. To compare consistency in gene
expression between brain regions, replicate means were plotted
in pair-wise Difference vs. Average (MA) plots (Fig. 2, A–C)
(21). Briefly, the log2 average signal intensity (A) was plotted
on the abscissa and the log2 difference between replicates (M)
was plotted on the ordinate. These scatter plots illustrate
pair-wise differences in signal intensity relative to the mean
signal intensity for each expressed gene. From each MA plot,
the percentage of genes having a signal intensity difference of
2 log2 units (¥) was calculated and reported for each pair-
wise comparison. Differences were greatest between BNST
and dStr (Fig. 2A, ¥ 1.91), while differences were minimal
between NAc and dStr (Fig. 2C, ¥  0.30). This finding is not
surprising as BNST and dStr are the most disparate in cell
types, while dStr and NAc are highly similar (predominantly
medium spiny neurons with a small population of cholinergic
and GABAergic interneurons) (37, 58, 59).
A Priori Analysis of Common Neurotransmitter Systems
The expression profile of the most differential a priori genes
was displayed in dChip (Fig. 3). Analysis of genes representing
common neurotransmitter systems and calcium binding pro-
teins revealed distinct patterns of expression, many of which
are consistent with previously reported data (see below). Hi-
erarchical cluster analysis on the individual samples correctly
grouped replicates in all three regions. Samples also were
divided into two further clusters (labeled 1 and 2, Fig. 3) with
NAc and dStr residing in the same cluster. This is the same
trend that was seen when all expressed genes were analyzed, as
the percentage of genes with signal intensity 2 log2 units (¥)
Table 2. Differentially expressed genes involved in
cAMP-dependent signaling as revealed by Ingenuity
pathway analysis
A. BNST vs. dStr
Description RAV q Value
Glutamate receptor, metabotropic 4 2.6 0.002
Phosphodiesterase 10A 39.9 0.002
Protein phosphatase 3 (formerly 2B), catalytic
subunit, alpha isoform (calcineurin A alpha) 1.9 0.003
Calcium/calmodulin-dependent protein kinase I 2.9 0.004
GNAS complex locus 2.5 0.004
Adenylate cyclase 2 (brain) 1.6 0.005
Calmodulin 2 (phosphorylase kinase, delta) 2.2 0.005
Calcium/calmodulin-dependent protein kinase IV 9.9 0.005
Calcium/calmodulin-dependent protein kinase
(CaM kinase) II delta 7 0.005
Regulator of G protein signaling 4 6.1 0.005
A kinase (PRKA) anchor protein (yotiao) 9 2.3 0.006
Opioid receptor, kappa 1 4.1 0.006
Phosphodiesterase 7B 5.1 0.006
Rap guanine nucleotide exchange factor (GEF) 3 2.3 0.006
B. BNST vs. NAc
Description RAV q Value
Adenosine A1 receptor 1.7 0.044
Glutamate receptor, metabotropic 4 1.8 0.044
Phosphodiesterase 4B, cAMP-specific
(phosphodiesterase E4 dunce homolog,
Drosophila) 2.0 0.048
Dopamine receptor D2 2.7 0.052
5-Hydroxytryptamine (serotonin) receptor 7
(adenylate cyclase-coupled) 1.8 0.052
Opioid receptor, kappa 1 4.8 0.052
Protein kinase, cAMP-dependent, regulatory,
type II, beta 2.7 0.056
Dopamine receptor D1 6.2 0.061
Adenylate cyclase 5 2.3 0.062
Phosphodiesterase 10A 6.4 0.063
Calcium/calmodulin-dependent protein kinase
(CaM kinase) II gamma 1.5 0.065
Rap guanine nucleotide exchange factor (GEF) 3 1.5 0.065
C. NAc vs. dStr
Description RAV q Value
Adenylate cyclase 1 (brain) 2.0 0.014
Guanine nucleotide binding protein (G protein),
alpha inhibiting activity polypeptide 1 1.5 0.014
Phosphodiesterase 10A 7.0 0.014
Phosphodiesterase 1A, calmodulin-dependent 6.0 0.014
Protein kinase, cAMP-dependent, regulatory,
type II, alpha 2.0 0.014
Regulator of G protein signaling 4 3.6 0.014
Rap guanine nucleotide exchange factor (GEF) 3 1.5 0.017
Dopamine receptor D2 2.6 0.018
Phosphodiesterase 7B 2.7 0.022
Calmodulin 2 (phosphorylase kinase, delta) 1.5 0.025
Rap guanine nucleotide exchange factor (GEF) 4 1.7 0.025
A kinase (PRKA) anchor protein (yotiao) 9 2.6 0.026
Calcium/calmodulin-dependent protein kinase IV 3.5 0.026
Calcium/calmodulin-dependent protein kinase
(CaM kinase) II alpha 2.3 0.029
Calcium/calmodulin-dependent protein kinase I 2.3 0.031
Phosphodiesterase 1B, calmodulin-dependent 1.9 0.036
Mitogen-activated protein kinase kinase 1 1.5 0.052
Adenosine A1 receptor 1.8 0.058
Regulator of G protein signaling 2, 24 kDa 1.5 0.062
Positive relative abundance value (RAV) indicates higher values in the 2nd
brain region of each comparison.
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was lowest between the NAc and dStr (¥  0.30, Fig. 2).
Expression levels of genes were grouped into four primary
clusters (Fig. 3). The most differentially expressed genes in
cluster A were corticotropin releasing hormone (Crh) and 	1
subunit of GABAA receptor (Gabrb1), where a trend for the
greatest enrichment in BNST relative to dStr. The BNST is
known to have neurons that contain corticotropin releasing
hormone (CRH/CRF) (83, 92). CRF projections from the
amygdala are known to project to the NAc (92), although some
medial NAc neurons have also been reported to contain CRF
(57, 73). In situ hybridization data from the Allen Brain Atlas
(3) illustrate the same trend of Crh expression being greatest in
the BNST relative to the NAc or dStr (Fig. 4). Cluster B
contained three genes that were lower in dStr relative to BNST
and NAc. Two of these genes have to do with GABAergic
signaling: the GABA transporter Slc6a1 and the 
5 GABAA
receptor subunit Gabra5. While GABAergic neurons are prev-
alent in the dStr, Slc6a1 (GAT-1) is only reported to be present
in 3–5% of striatal neurons (6). Additionally, striatal 
5
GABAA receptor subunit immunoreactivity is very low, al-
though levels in the BNST were also reported to be low (84).
Cluster C represents just over half of the genes, where the trend
is for elevated expression in the dStr, moderate expression in
the NAc, and low expression in the BNST. The most divergent
region of this cluster also contains two genes involved
in GABAergic signaling, the GABAA receptor subunits 
(Gabrd) and 
4 (Gabra4). Immunoreactivity for the  subunit
was previously shown to be higher in NAc and dStr than BNST
and 
4 immunoreactivity ranked in the same order as the
expression pattern in the cluster diagram: highest in dStr,
moderate in NAc, and lowest in BNST (84). Analysis of EGFP
expression from a Penk1 reporter mouse revealed the same
trend of expression as cluster analysis for Penk1 (Figs. 3 and 5).
Specifically, expression was highest in the dStr and lower in
NAc and BNST. Cluster D represents genes enriched in NAc
and includes prodynorphin (Pdyn) and the AMPA glutamate
receptor 1 subunit (Gria1,GluR1). Prodynorphin immunoreac-
tivity has been reported to be present in very high levels in
NAc relative to dStr in rodents (112) and humans (52), al-
though its presence has also been described in BNST of the rat
(26). In the primate, GluR1 has been described as higher in the
NAc than the dStr (70).
FCS Analysis of Brain Regions
BNST vs. dStr. FCS was performed using 19,557 probe
sets found to be present in at least one of the two brain
regions (see MATERIALS AND METHODS for details). Table 1A
shows the 11 Gene ontology (GO) classes that were signif-
icantly different between the BNST and striatum (Str). The
Table 3. Differentially expressed genes involved in calcium signaling as revealed by Ingenuity pathway analysis
A. BNST vs. dStr
Function Description RAV q Value
Ion channel glutamate receptor, ionotropic, kainate 1 8.0 0.003
Ion channel glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 3.5 0.003
Phosphatase protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) 1.9 0.003
Ion channel calcium channel, voltage-dependent, L type, alpha 1C subunit 1.8 0.004
Kinase calcium/calmodulin-dependent protein kinase I 2.9 0.004
Transporter solute carrier family 8 (sodium/calcium exchanger), member 1 8.0 0.004
Other calcium/calmodulin-dependent protein kinase (CaM kinase) II delta 7.0 0.005
Kinase calcium/calmodulin-dependent protein kinase IV 9.9 0.005
Kinase calcium/calmodulin-dependent protein kinase kinase 2, beta 4.6 0.005
Kinase calmodulin 2 (phosphorylase kinase, delta) 2.2 0.005
B. NAc vs. dStr
Function Description RAV q Value
Other tropomyosin 1 (alpha) 3.6 0.013
Ion channel calcium channel, voltage-dependent, beta 2 subunit 1.7 0.014
Kinase protein kinase, cAMP-dependent, regulatory, type II, alpha 2.0 0.014
Ion channel transient receptor potential cation channel, subfamily C, member 3 2.4 0.014
Transporter ATPase, Ca2 transporting, plasma membrane 2 2.4 0.016
Ion channel calcium channel, voltage-dependent, gamma subunit 4 2.2 0.017
Transporter solute carrier family 8 (sodium/calcium exchanger), member 1 5.8 0.018
Kinase calcium/calmodulin-dependent protein kinase kinase 2, beta 3.0 0.024
Other calmodulin 2 (phosphorylase kinase, delta) 1.5 0.025
Kinase calcium/calmodulin-dependent protein kinase IV 3.5 0.026
Kinase calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha 2.3 0.029
Kinase calcium/calmodulin-dependent protein kinase I 2.3 0.031
Kinase calcium/calmodulin-dependent protein kinase ID 1.9 0.031
Ion channel calcium channel, voltage-dependent, gamma subunit 2 2.5 0.033
Ion channel calcium channel, voltage-dependent, beta 4 subunit 1.6 0.036
Transporter ATPase, Ca2 transporting, plasma membrane 1 2.0 0.038
Ion channel inositol 1,4,5-triphosphate receptor, type 1 2.0 0.039
Ion channel glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 2.7 0.04
Other calsequestrin 2 (cardiac muscle) 2.3 0.043
Ion channel ryanodine receptor 1 (skeletal) 2.0 0.055
Positive RAV indicates higher values in the 2nd brain region of each comparison.
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most significantly different class was potassium ion trans-
port (GO:0006813), with 78 genes contributing to this
result. Several of the GO classes were associated with
G-coupled protein receptor (GPCR) signaling, including G
protein signaling, coupled to IP3 second messenger (GO:
0007200), adenylate cyclase activation (GO:0007190), cy-
clic nucleotide biosynthesis (GO:0009190), G protein signal-
ing, adenylate cyclase activating pathway (GO:0007189), and
positive regulation of small GTPase-mediated signal transduc-
tion (GO:0051057). This trend suggests that neurotransmission
likely differs in fundamental ways between the BNST and dStr
in several types of G-coupled protein receptor systems.
BNST vs. NAc. FCS was performed on 19,025 probe sets for
the comparison of BNST and NAc. Six GO classes were
identified as unique between these two regions (Table 1B).
These were less specific than those identified in BNST vs. dStr.
Some GO classes such as detection of chemical stimulus
(GO:0009593) and calcium ion (GO:0005513) may be directly
related to neural transmission, while other classes included
diverse processes.
NAc vs. dStr. Of 19,557 probe sets analyzed, FCS analysis
detected eight significant GO classes different between the
NAc and dStr (Table 1C). Exocytosis was represented by two
GO classes (GO:0006887 and GO:0017157). FCS also re-
vealed differences between the NAc and dStr in cellular and/
or synaptic remodeling: angiogenesis (GO:0001525), positive
regulation of neurogenesis (GO:0050769), and cell-cell adhe-
sion (GO:0016337). The accumbens was also found to differ
from the dStr in a similar pathway, extracellular matrix orga-
nization and biogenesis (GO:0030198, Table 1B).
IPA
In contrast to FCS analysis, IPA only analyzes genes differ-
entially expressed in pair-wise compared brain regions, called
“focus genes” (see MATERIALS AND METHODS). First, unpaired
t-tests were performed on the genes present in at least one
region (19,557, 19,025, and 19,557 genes for BNST/NAc,
BNST/Str, and NAc/Str pair-wise comparisons, respectively.)
From these comparisons, genes were found to be differentially
expressed by stringent criteria (see MATERIALS AND METHODS for
details) were submitted to IPA (177, 196, and 373 focus genes
were found for BNST/NAc, BNST/Str, and NAc/Str pair-wise
comparisons.) Figure 6 shows the pathways found to be sig-
nificantly different in at least one pair-wise analysis using IPA.
Similar to FCS analysis, cyclic adenosine monophosphate
(cAMP)-mediated signaling, calcium signaling, and G-coupled
protein receptor signaling pathways were the most distinct
among the three regions studied. These types of signaling are
prominent in many brain regions, but the data suggest that
Fig. 7. In situ hybridization showing enrichment of Camk4 in dStr. Coronal sections of mouse brain showing high expression of Camk4 in the dStr relative to
NAc and BNST. Images taken from the Allen Brain Atlas (www.brain-map.org). Image IDs: Camk4_370_0303121839 (left) and Camk4_322_0303111783
(right).
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there are differences in the specific gene products involved in
these signaling pathways between the BNST, NAc, and dStr.
For example, phosphodiesterases (PDEs) are unique to each
region, the most marked result being that Pde10a is highly
enriched in dStr relative to both BNST and NAc (Table 2b).
The PDE isoform encoded by Pde10a is unique in that it
hydrolyzes both cAMP and cGMP (32). It has been previously
reported to be enriched in Str (32, 33), where it plays a critical
role in modulating activity of striatal neurons (103). Tran-
scripts of particular adenylate cyclase isoforms are also en-
riched in each brain region. For example, adenylate cyclase 2
(Adcy2) is enriched in the BNST relative to Str. This isoform
is stimulated by PKC (55) and by both Gs
 as and G	
subunits, where it is though to serve as a coincidence detector
stimulated by G	 subunits in the context of activation by Gs

(16, 107). This suggests that adenylate cyclase activity within
the BNST could be stimulated by a greater variety of GPCRs
than as just Gs
. IPA also identified Adcy5 (adenylate cyclase
5) as being enriched in NAc relative to BNST (Table 2B) and
Adcy1 (adenylate cyclase 1) as enriched in dStr relative to NAc
(Table 2C). Activity of the adenylate cyclase (AC) 5 isoform is
inhibited by calcium/calmodulin, while AC1 is stimulated by
calcium/calmodulin (for review, see Ref. 106). Also within the
adenylate cyclase signaling pathway, regulator of G-coupled
Table 4. Differentially expressed genes involved in G-coupled protein receptor signaling as revealed by Ingenuity
pathway analysis
A. BNST vs. dStr
Function Description RAV q Value
G protein-coupled receptor glutamate receptor, metabotropic 4 2.6 0.002
G protein-coupled receptor endothelin receptor type B 3.9 0.003
Enzyme GNAS complex locus 2.5 0.004
Enzyme adenylate cyclase 2 (brain) 1.6 0.005
Kinase v-akt murine thymoma viral oncogene homolog 2 2.3 0.005
Kinase calcium/calmodulin-dependent protein kinase IV 9.9 0.005
Kinase calcium/calmodulin-dependent protein kinase (CaM kinase) II delta 7.0 0.005
Other regulator of G protein signaling 4 6.1 0.005
G protein-coupled receptor opioid receptor, kappa 1 4.1 0.006
Kinase protein kinase C, beta 1 2.7 0.006
Other Rap guanine nucleotide exchange factor (GEF) 3 2.3 0.006
B. BNST vs. NAc
Function Description RAV q Value
G protein-coupled receptor endothelin receptor type B 2.6 0.026
G protein-coupled receptor adenosine A1 receptor 1.7 0.044
G protein-coupled receptor glutamate receptor, metabotropic 4 1.8 0.044
Enzyme phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila) 2.0 0.048
G protein-coupled receptor dopamine receptor D2 2.7 0.052
G protein-coupled receptor 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled) 1.8 0.052
G protein-coupled receptor opioid receptor, kappa 1 4.8 0.052
Kinase protein kinase, cAMP-dependent, regulatory, type II, beta 2.7 0.056
G protein-coupled receptor dopamine receptor D1 6.2 0.061
Enzyme adenylate cyclase 5 2.3 0.062
Kinase calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma 1.5 0.065
Other Rap guanine nucleotide exchange factor (GEF) 3 1.5 0.065
C. NAc vs. dStr
Function Description RAV q Value
Enzyme adenylate cyclase 1 (brain) 2.0 0.014
G protein-coupled receptor endothelin receptor type B 1.5 0.014
Enzyme guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 1.5 0.014
Enzyme phosphodiesterase 1A, calmodulin-dependent 6.0 0.014
Kinase protein kinase, cAMP-dependent, regulatory, type II, alpha 2.0 0.014
Other regulator of G protein signaling 4 3.6 0.014
Enzyme phospholipase C, beta 1 (phosphoinositide-specific) 3.0 0.015
Other Rap guanine nucleotide exchange factor (GEF) 3 1.5 0.017
G protein-coupled receptor dopamine receptor D2 2.6 0.018
Enzyme v-Ha-ras Harvey rat sarcoma viral oncogene homolog 1.9 0.023
Kinase calcium/calmodulin-dependent protein kinase IV 3.5 0.026
Kinase calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha 2.3 0.029
Enzyme phosphodiesterase 1B, calmodulin-dependent 1.9 0.036
Kinase mitogen-activated protein kinase kinase 1 1.5 0.052
Kinase protein kinase C, beta 1 1.8 0.052
G protein-coupled receptor adenosine A1 receptor 1.8 0.058
Other regulator of G-protein signaling 2, 24 kDa 1.5 0.062
Positive RAV indicates higher values in the second brain region of each comparison.
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signaling (RGS)2 and RGS4, enzymes that attenuate signaling
through G-coupled protein receptors, showed differential en-
richment of transcripts (Rgs2 and Rgs4, respectively). Isoforms
of these enzymes have different target specificities, where
RGS2 inhibits Gq
 and AC5 (which had enriched transcript
levels in NAc), but not AC1 or AC2 (enzymes whose tran-
scripts were enriched in dStr and BNST, respectively) (102),
and RGS4 inhibits Gi/o
 (9, 111) and Gq
 (47). RGS2 and
RGS4 are intimately related to dopaminergic signaling, as
transcription is regulated by D1 and D2 dopamine receptors,
respectively (35, 54), and RGS4 polymorphisms have been
associated with schizophrenia in human populations (43). Like
adenylate cyclase, calcium/calmodulin-dependent protein ki-
nase (CaMK) isoforms are also differentially enriched in all
three brain regions and have different means of transduction.
The CaMKs are a prevalent family of kinases that are crucial
to neural function, representing 1% of total brain protein (for
review, see Refs. 41, 90). The most common is CaMKII,
which phosphorylates numerous proteins and is involved in
diverse processes such as neural plasticity, exocytosis, and gene
transcription (90). Other CaMK isoforms can have unique sub-
strates. For example, unlike the multifunctional CaMKs,
CaMKIV is capable of phosphorylating cAMP-dependent pro-
tein kinase (PKA) substrates and the GTP-binding protein
Rap1B (41, 91). It is also unique in that unlike most CaMKs it
is monomeric and contains a nuclear localization sequence
(90). CaMKIV transcript (Camk4) was enriched in dStr relative
to BNST and NAc (Tables 2, A and C, and 3, A and B), a
finding that was consistent with in situ hybridizationdata from
the Allen Brain Atlas (Fig. 7). CaMKIV phosphorylates cAMP
response element binding protein (CREB), stimulating CREB-
mediated transcription, whereas CaMKII phosphorylates an
additional site that prevents CREB activation (23, 105). Con-
sistent with the observed differences in adenylate cyclases,
PDEs, and RGSs, which also relate to G-coupled receptor
signaling, IPA identified GPCR signaling as unique among all
three brain regions (Fig. 6), while the majority of the genes
contributing to this result were included in the more signifi-
cantly different pathways (Table 4).
IPA also identified other canonical pathways that differed
between brain regions (Fig. 6). Pair-wise comparisons between
the dStr and both the NAc and BNST revealed chemokine
signaling as differentially regulated, although the majority of
the genes contributing to this effect were included in the
calcium signaling pathway (Supplemental Table S3). ERK-
MAPK signaling was different between the dStr and NAc
(gene list in Table 5), with eight of 13 significantly different
transcripts higher in NAc than dStr. Differences in ERK-
MAPK signaling between these two regions is not surprising,
as neural ERK-MAPK signaling is highly associated with
responses to stress (72, 99) and drugs of abuse (108), both of
which are mediated to a greater extent by the NAc than the dStr
(8, 11, 19). The gene most significantly contributing to this
finding was histone H3.3B (H3f3b, Table 5). Histone 3.3B is a
member of the H3.3 family of replacement histones which
incorporate into the open chromatin of active genes in a
replication-independent manner (2, 40, 46). Additionally, rel-
ative to the canonical H3, H3.3 variants have been shown to
have two- to fivefold greater transcription-promoting modifi-
cations (i.e., acetylation and methylation) than the H3 (71),
suggesting that an enrichment of H3.3 could be associated with
greater induction of transcription in the NAc relative to dStr.
Additional differences between regions found with IPA include
dopamine signaling, IGF-1 signaling, and cardiac 	-adrenergic
signaling (Fig. 6).
In an effort to cross-validate our findings with independently
obtained data, we downloaded microarray data from a publicly
available database (http://www.barlow-lockhart-brainmapnimhgrant.
org/) (120). Microarray data from this database were obtained
using tissue from male C57BL/6J and 129S6/SvEvTac (two
mice each) (120). This database includes expression data from
two of the three brain regions investigated in the current study
(Str and BNST). Data from Str and BNST were downloaded
and filtered using the following criteria: 1) 3/4 P calls in at least
one brain region, 2) fold difference 1.5, and 3) signal
intensity difference 80. Unpaired t-tests were performed
for pair-wise comparison of Str and BNST. The Benjamini-
Hochberg procedure was used to derive q-values, and false
discovery rate was controlled at 1%. IPA performed on the
Barlow-Lockhart data revealed significantly different path-
ways with a high degree of overlap with our data (Table 6).
Importantly, the three most significantly different pathways
identified using our own data were also among the top five
pathways detected with the same analysis using indepen-
Table 5. Differentially expressed genes involved in mitogen-activated protein kinase/extracellular signal-regulated kinase
signaling as revealed by Ingenuity pathway analysis
NAc vs. dStr
Function Description RAV q Value
Other H3 histone, family 3B (H3.3B) 1.8 0.014
Kinase protein kinase, cAMP-dependent, regulatory, type II, alpha 2.0 0.014
Transcription regulator v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 1.8 0.016
Other Rap guanine nucleotide exchange factor (GEF) 3 1.5 0.017
Other talin 2 2.0 0.018
Kinase ribosomal protein S6 kinase, 90 kDa, polypeptide 5 2.7 0.022
Enzyme v-Ha-ras Harvey rat sarcoma viral oncogene homolog 1.9 0.023
Other tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide 1.6 0.025
Other tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide 1.7 0.041
Kinase p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 1.9 0.050
Kinase mitogen-activated protein kinase kinase 1 1.5 0.052
Kinase protein kinase C, beta 1 1.8 0.052
Phosphatase protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform 1.8 0.063
Positive RAV indicates higher values in dStr.
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dently acquired data (120). Additionally, six of the top 10
pathways IPA originally identified were also included in the
top 10 pathways identified using the Barlow-Lockhart data.
It is important to note that this consistency is observed
despite the significantly different methodology used to ob-
tain the datasets. The Barlow-Lockhart data were obtained
from two different mouse strains (C57BL/6J and 129S6/
SvEvTac) by different dissection methods (gross dissection
of whole brain regions). The samples were also analyzed
using a different microarray platform (Affymetrix GeneChip
MG_U74Av2) that has a less complete array of probe sets
(12,422 vs. 43,000).
To further cross-validate to our findings with independently
obtained data, we analyzed cellular expression of genes from
five most significantly different canonical pathways (Fig. 6)
using publicly available in situ hybridization data from the Allen
Brain Atlas (www.brain-map.org). Regression analysis on pair-
wise comparisons significantly different in these Ingenuity path-
ways demonstrated a high degree of concordance between mi-
croarray and in situ hybridization data (Fig. 8, A and B). One
factor contributing to differences, however, was that some of
the pair-wise differences appeared greater in the degree of
expression in cells rather than the number of cells that were
labeled. This type of difference would be more likely to be
detected by microarray than with in situ hybridization coupled
with cell counting procedures. Nonetheless, there is consis-
tency in relative abundance values despite the differences in
quantification techniques (whole tissue RNA vs. number of
cells positive for probe labeling).
As a final validation of our findings, we used qPCR as an
additional measure of relative transcript abundance in the
BNST, dStr, and NAc. Genes were selected from pair-wise
analyses within the cAMP-dependent signaling pathway from
IPA (Table 2, A–C). Relative abundance values obtained using
qPCR showed trends of gene expression consistent with mi-
croarray data (Fig. 9). Additionally, all but one of the selected
genes found to be significantly different in pair-wise analysis
Table 6. Rank order of significant pathways in the present
study and from the Barlow-Lockhart database
Pathway Present Study Barlow-Lockhart
cAMP-mediated signaling 1 1
G protein-coupled receptor signaling 2 4
IGF-1 signaling 3 3
Glutamate receptor signaling 4 25
Calcium signaling 5 28
Insulin receptor signaling 6 6
Chemokine signaling 7 2
VEGF signaling 8 18
GM-CSF signaling 9 7
Cardiac 	-adrenergic signaling 10 12
Ingenuity pathway analysis performed on BNST vs. dStr in the present
analysis revealed 10 significant pathways. The analysis was repeated using
publicly available microarray data from the same brain regions (available at
http://www.barlow-lockhart-brainmapnimhgrant.org/).
Fig. 8. Regression analysis of differential gene expression reported by microarray and post hoc analysis from the Allen Brain Atlas. A: representative scatter plot
of fold difference reported by microarray (x-axis) and Allen Brain Analysis (y-axis). Plot shown is for genes within the cyclic AMP signaling pathway in the
BNST vs. striatum (Str) pair-wise analysis. B: R-values for pair-wise analyses found to be significant among the top 5 distinct canonical pathways reported by
Ingenuity pathway analysis (see also Fig. 6). Pair-wise analyses not found to be significant by Ingenuity were not analyzed and are blacked out.
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using microarray were also found to be significantly different
using qPCR (Table 7).
DISCUSSION
The present data suggest that transcriptome differences
across these regions may in part underlie previously observed
signaling differences. The brain regions studied reflect neuro-
anatomical targets relevant to Parkinson’s disease, Hunting-
ton’s disease, drug abuse, and anxiety. Using a priori analysis,
FCS, and IPA, we have identified differences in gene expres-
sion that contribute to differences in biochemical pathways
crucial to neurotransmission.
A Priori Analysis
A priori analysis showed several trends consistent with
neuroanatomical studies using other methods of detection.
First, identification of genes within neuropeptide systems re-
flecting known differences among the three regions were in-
vestigated. Known localization of corticotropic releasing hor-
mone (CRH) signaling was recapitulated by high expression of
transcripts for corticotropic releasing hormone (Crh) and CRH
binding protein (Crhbp) in the BNST and NAc, but not Str (57,
73, 83). Levels of prodynorphin (Pdyn) and proenkephalin
(Penk1) transcripts also reflected established patterns of the
respective peptides. These peptides are unique in that they are
expressed in a mutually exclusive manner within medium
spiny neurons (the primary neuron type of the Str and NAc)
(39). In the NAc, prodynorphin immunoreactivity is expressed
in very high levels relative to the dorsal Str in rodents (112)
and humans (52). Likewise, enkephalin expression is greater in
the Str than the NAc (49, 85), and presence of enkephalin has
been described in the BNST (62, 85, 86). A priori analysis in
the present study also revealed the same pattern of elevated
prodynorphin (Pdyn) in NAc relative to Str and higher levels of
proenkephalin gene (Penk1) in Str relative to NAc, while levels
of both peptides were lowest in BNST. This expression pattern
was further confirmed in the Penk1-EGFP BAC-transgenic
mouse.
A priori analysis also revealed expression patterns of nor-
adrenergic receptors consistent with phenotypic data. The al-
pha2 adrenergic receptors alpha2a (Adra2a) and alpha2c
(Adra2c) are highly similar in that they show 70% sequence
homology and both couple to the same class of signal trans-
duction mechanisms (45, 68), although they differ in the fact
that alpha2a, but not alpha2c is prone to agonist-induced
desensitization (66). Despite these similarities, genetic studies
have shown divergent phenotypes controlled by Adra2a and
Adra2c (for review see Ref. 60). Targeted deletion of Adra2a
leads to a high-anxiety/depressive phenotype (97), while
Adra2c deletion showed a resistance to depressive behavior
(93). Both anxiety and depression have been linked to norad-
renergic transmission within the BNST (75), where we found
the highest expression of Adra2a. Adra2c null mutants also
have a heightened locomotor response to amphetamine (94).
Consistent with other reports (42, 77), we found Adra2c to be
highly expressed in Str relative to other regions investigated,
and the enhanced amphetamine locomotor response is consis-
tent with altered striatal transmission (14).
Pathway Analysis
FCS and IPA revealed the most significantly different physio-
logical classes and pathways based on gene expression values.
Fig. 9. qPCR validation of select genes from Ingenuity pathway analysis. Relative abundance values (RAV) of transcript between brain regions was calculated
by microarray and qPCR. Positive RAV indicates higher values in the 2nd brain region of each comparison. Statistical analyses of pair-wise comparisons between
brain regions for microarray and qPCR are in Table 7.
Table 7. qPCR validation of select genes revealed by
Ingenuity pathway analysis
Gene Comparison
Microarray Significance
(Ingenuity q Value)
qPCR
Significance
Adcy2 BNST vs. Str 0.005 n.s.
Akap9 BNST vs. Str 0.006 †
Gnas BNST vs. Str 0.004 †
Pde7b BNST vs. Str 0.006 †
Pde10a BNST vs. Str 0.002 †
Rgs4 BNST vs. Str 0.005 †
Camk2 g BNST vs. NAc 0.065 *
Drd2 BNST vs. NAc 0.052 †
Pde10a BNST vs. NAc 0.063 †
Htr7 BNST vs. NAc 0.052 †
Adcy5 BNST vs. NAc 0.062 †
Pde7b NAc vs. Str 0.022 †
Pde10a NAc vs. Str 0.014 †
Drd2 NAc vs. Str 0.018 †
Rgs4 NAc vs. Str 0.025 †
Select genes from the cAMP-dependent signaling pathway identified by
Ingenuity pathway analysis were analyzed by qPCR. Mean normalized expres-
sion values were compared using corrected t-tests. Significance from Ingenuity
analyses (see also Table 2) is shown for comparison. *P  0.05, †P  0.01.
n.s., Not significant.
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One overall trend observed was that numerous functional classes
and pathways associated with synaptic plasticity, a cellular form
of learning, are different between the brain regions investigated.
FCS identified several plasticity related processes, including ad-
enylate cyclase activation (GO:0007190), regulation of synaptic
transmission (GO:0050804), and detection of calcium ion (GO:
0005513) as different between regions, and the top three
pathways identified by IPA are all involved in synaptic plas-
ticity (for review, see Ref. 69). While synaptic plasticity is
associated with learning in general, plasticity within some
brain regions is thought to be associated with enduring behav-
ioral maladaptations such as drug seeking, depression, and
chronic anxiety states (12, 53, 98, 115). Identification of exact
molecular targets involved in region-specific plasticity is thus
invaluable to the development of pharmaceuticals that may aid
in the treatment of neurological disorders involving maladap-
tive learning.
While both FCS and IPA identified genes and pathways that
play a role in plasticity as being different between the BNST,
Str, and NAc, IPA revealed specific molecules that may regu-
late plasticity within individual regions. Several genes associ-
ated with inhibition of long-term potentiation (LTP) were
revealed to be enriched in Str and NAc relative to the BNST.
Specifically, phosphodiesterases (10A, 7B, and 4B) and protein
phosphatase 3 were higher in Str or NAc than BNST. Recruit-
ment of cAMP plays an important role in LTP in a number of
systems (for review, see Ref. 69). In particular, inhibition of
cAMP phosphodiesterases can facilitate LTP (7) and memory
(87). The BNST also has a higher representation of genes
associated with enhanced LTP than Str and NAc, including
Gnas, Rapgef3, Htr7, and Adcy2. Consistent with these trends,
data from our own lab also suggest regional differences in
plasticity between the BNST and NAc. Specifically, a stimulus
protocol effective in producing LTP in the BNST is inef-
fective in the NAc (96, 113). While LTP in several brain
regions including the Str are dependent on L-type calcium
channels (56, 78), LTP in the BNST is not (113). Similar to
this electrophysiological finding, stimulation of L-type cal-
cium channels induced robust activation of the transcription
factor CREB in Str, but not in the BNST (67). These
physiological phenomena were mirrored by IPA, which
revealed a paucity of an integral component of the L-type
calcium channel (Cacna1c) in BNST relative to Str (see
Table 3). Furthermore, stimulation of the dopamine D1
receptor activates the transcription factor CREB (cyclic
AMP response element binding protein) more effectively in
the BNST than the dStr, even though there are fewer D1
receptors in BNST (67). Finally, the idea of the Str being
more resistant to LTP is supported by IPA identification of
the catalytic subunit of calcineurin, a negative regulator of
LTP (116), as being elevated in Str relative to BNST.
Using this methodology, we successfully performed mi-
croarray analysis on individual brain regions with the precision
of using 500 m diameter tissue punches from 300 m slices
of fresh tissue. This technique yields high-quality RNA from
discrete brain regions without the sample preparation, technical
difficulty, or expense of laser capture microdissection (95).
While the power to detect differences between brain regions
may be reduced by low sample sizes (three replicates per brain
region), our results were consistent with validation procedures.
Cross-validation of genes identified in a priori analysis (Crh
and Penk1) and IPA using in situ hybridization data from the
Allen Brain Institute (3) and a reporter mouse revealed similar
anatomical specificity of enrichment. Additionally, indepen-
dently obtained data analyzed with IPA, cell counting tech-
niques, and qPCR yielded results highly consistent with those
obtained by microarray analysis.
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